Velo3D vs Markforged Which Is More Promising?

Velo3D and Markforged are two leading companies in the additive manufacturing industry, each offering unique technologies and products to their customers. Velo3D's focus on metal 3D printing with its Sapphire system has garnered attention for its ability to produce complex, high-quality parts with minimal post-processing. On the other hand, Markforged's emphasis on composite and metal 3D printing with its Industrial Series printers has made it a popular choice among manufacturers looking for robust and versatile solutions. Both companies have seen significant growth in recent years, making their stocks a point of interest for investors looking to capitalize on the expanding additive manufacturing market.

Velo3D

Markforged

Stock Price
Day Low$1.24
Day High$1.36
Year Low$0.30
Year High$58.10
Yearly Change19266.67%
Revenue
Revenue Per Share$5.50
5 Year Revenue Growth-0.60%
10 Year Revenue Growth-0.60%
Profit
Gross Profit Margin-0.76%
Operating Profit Margin-2.67%
Net Profit Margin-2.23%
Stock Price
Day Low$3.78
Day High$3.90
Year Low$1.57
Year High$8.80
Yearly Change459.80%
Revenue
Revenue Per Share$0.43
5 Year Revenue Growth-0.74%
10 Year Revenue Growth-0.74%
Profit
Gross Profit Margin0.49%
Operating Profit Margin-0.79%
Net Profit Margin-1.01%

Velo3D

Markforged

Financial Ratios
P/E ratio-0.10
PEG ratio0.00
P/B ratio0.21
ROE-154.92%
Payout ratio0.00%
Current ratio1.69
Quick ratio0.47
Cash ratio0.05
Dividend
Dividend Yield-%
5 Year Dividend Yield0.00%
10 Year Dividend Yield0.00%
Velo3D Dividend History
Financial Ratios
P/E ratio-8.88
PEG ratio0.22
P/B ratio7.97
ROE-69.65%
Payout ratio0.00%
Current ratio2.39
Quick ratio1.98
Cash ratio1.13
Dividend
Dividend Yield-%
5 Year Dividend Yield0.00%
10 Year Dividend Yield0.00%
Markforged Dividend History

Velo3D or Markforged?

When comparing Velo3D and Markforged, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Velo3D and Markforged.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Velo3D has a dividend yield of -%, while Markforged has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Velo3D reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Markforged reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Velo3D P/E ratio at -0.10 and Markforged's P/E ratio at -8.88. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Velo3D P/B ratio is 0.21 while Markforged's P/B ratio is 7.97.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Velo3D has seen a 5-year revenue growth of -0.60%, while Markforged's is -0.74%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Velo3D's ROE at -154.92% and Markforged's ROE at -69.65%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $1.24 for Velo3D and $3.78 for Markforged. Over the past year, Velo3D's prices ranged from $0.30 to $58.10, with a yearly change of 19266.67%. Markforged's prices fluctuated between $1.57 and $8.80, with a yearly change of 459.80%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.

Comparision